Navigation Links
NCI awards $1.7 million to cancer specialist at Children's Hospital Los Angeles

LOS ANGELES (April 12, 2011) Fatih Uckun, MD, PhD, head of Translational Research in Leukemia and Lymphoma at the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, and a research professor of Pediatrics at the Keck School of Medicine of the University of Southern California, has been awarded $1.7 million from the National Cancer Institute (NCI) to support development of a new strategy to overcome the resistance of cancer cells to radiation therapy.

In spite of promising advances in some forms of cancer, especially childhood leukemia, the overall progress in cancer therapy has remained modest due to the resistance of cancer cells to contemporary radiation and chemotherapy regimens. A team of researchers led by Dr. Uckun, an investigator at The Saban Research Institute and a member of the Developmental Therapeutics Program of the USC Norris Comprehensive Cancer Center, has recently discovered that radiation-resistant cancer cells can be made radiation-sensitive by specifically inactivating a molecular target comprised of three important signaling proteins, namely polo-like kinase 1 (PLK1), spleen tyrosine kinase (SYK) and STAT3 transcription factor.

The group's translational research shows that rationally designed inhibitors of this molecular target markedly improve the potency of radiation therapy in animal models of radiation-resistant cancer. With an earlier $2.5 million dollar grant from NCI and the support of the National Cancer Institute Alliance for Nanotechnology in Cancer, Dr. Uckun and his team have been developing nanoparticle formulations of these inhibitors as promising drug candidates against cancer.

The goal of this new grant is to allow Dr. Uckun to further optimize the clinical potential of his innovative strategy as part of a multidisciplinary effort to overcome radiation resistance of cancer cells. In addition, Dr. Uckun and colleagues will try to identify so-called "biomarkers" that will help clinicians predict which patients would be most likely to benefit from this new strategy.

"Our long-term goal is to develop biomarker-guided, personalized radiation therapy regimens that are both more effective and have fewer side effects," said Dr. Uckun. "We are grateful to NCI for this opportunity to work towards a practical solution for one of the most urgent unmet challenges in cancer therapy." The main therapeutic target for this five-year research project will be the most aggressive and radiation-resistant forms of childhood leukemia and will include detailed efficacy and safety studies to evaluate clinical potential of the lead experimental anti-cancer drug candidate.


Contact: Ellin Kavanagh
Children's Hospital Los Angeles

Related medicine news :

1. NSF awards grant to University of Houston professor to develop color-coded MRIs
2. SEBM Young Investigator Awards for 2011
3. UCSD scientists receive prestigious Hartwell Biomedical Research Awards
4. American Cancer Society awards new research and training grants
5. AACR awards 50 minority scholar in cancer research awards
6. AACR and Landon Foundation support the next generation of researchers with INNOVATOR Awards
7. ESCEO Young Investigators Awards presented at ECCEO11-IOF in Valencia
8. Sea grant awards more than $1.1 million for research under EPAs Long Island Sound study
9. LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus
10. Bristol-Myers Squibb Foundation awards nearly $1M to HBV, HCV awareness, prevention and care
11. McKesson Foundation awards $1.3 million in 6 Mobilizing for Health Research grants
Post Your Comments:
Related Image:
NCI awards $1.7 million to cancer specialist  at Children's Hospital Los Angeles 
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: